Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ningbo Innovation Mechanish Bioscience LLC currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The case is being examined by STONEBRAKER, ALYSSA RAE, who is the 1 distinct examiner and the busiest examiner with 1 busiest examiner pending action. Prosecution is occurring in 1 distinct art unit.
For a practitioner, this data indicates that the entirety of the company's immediate prosecution success relies on the outcome of this 1 pending office action. Since there is only 1 distinct examiner involved, there are no competing examiner perspectives to navigate within the Biotechnology & Pharmaceuticals sector. The matching count of 1 pending office action and 1 busiest examiner pending action under STONEBRAKER, ALYSSA RAE means that all prosecution resources are directed toward a single point of contact. This concentration in 1 distinct art unit and under 1 distinct examiner allows for a highly specialized and streamlined communication strategy, though it also means the portfolio lacks the diversification that comes with multiple pending matters across different examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17759114 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | STONEBRAKER, ALYSSA RAE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17759114 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | STONEBRAKER, ALYSSA RAE | 1642 | §103 | Final Rejection | — | Pending | Jul 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNingbo Innovation Mechanish Bioscience LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alyssa Rae Stonebraker has the most, with 1 of Ningbo Innovation Mechanish Bioscience LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
